ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour
Badreddin Edris(Stanford Medicine), Matt van de Rijn(Stanford University), Robert B. West(Stanford University), Roel Nusse(Howard Hughes Medical Institute), Alexander J. Lazar(The University of Texas MD Anderson Cancer Center), Sonja E. Steigen(UiT The Arctic University of Norway), Thomas Mühlenberg(West Cancer Center), Dina Lev(Assuta Medical Center), Shirley Zhu(Stanford Medicine), Cheng‐Han Lee(University of Alberta), Andrew H. Beck(Brown University), Íñigo Espinosa(Hospital de Sant Pau), Kelli Montgomery(Stanford Medicine), Jonathan A. Fletcher(Harvard University), Amanda Mikels(Howard Hughes Medical Institute)
Cited by 77
Related Papers
Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women With Breast Cancer
|JAMA|2017|3.3k
Wnt signaling: a common theme in animal development
|Genes & Development|1997|2.6k
Purified Wnt5a Protein Activates or Inhibits β-Catenin–TCF Signaling Depending on Receptor Context
|PLoS Biology|2006|1.3k
A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging
|Cell|2018|1.2k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k